This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Oldenburg J, Mahlangu JN, Bujan, et al The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25: 33–44. doi: 10.1111/hae.13618.OldenburgJMahlanguJNBujanet alThe effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 StudyHaemophilia201925334410.1111/hae.13618Open DOISearch in Google Scholar
Zimowski KL, Batsuli GM, Reding MT, et al Maintaining perioperative hemostasis in patients with severe Hemophilia A and inhibitors receiving emicizumab prophylaxis. Blood 2018: 132 (Supplement 1):635. doi: 10.1182/blood-2018-99-115089.ZimowskiKLBatsuliGMRedingMTet alMaintaining perioperative hemostasis in patients with severe Hemophilia A and inhibitors receiving emicizumab prophylaxisBlood2018132Supplement 163510.1182/blood-2018-99-115089Open DOISearch in Google Scholar
Kruse-Jarres R, Callaghan MU, Croteau SE, et al Surgical experience in two multicenter, open label phase 3 studies of emicizumab in persons with Hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood 2017; 130 (Suppl): 89.Kruse-JarresRCallaghanMUCroteauSEet alSurgical experience in two multicenter, open label phase 3 studies of emicizumab in persons with Hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)Blood2017130Suppl8910.1182/blood.V130.Suppl_1.89.89Search in Google Scholar
Levy GG, Asikanius E, Kuebler P, et al Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J Thromb Haemost 2019;17:1470–7. doi: 10.1111/jth.14491.LevyGGAsikaniusEKueblerPet alSafety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical programJ Thromb Haemost2019171470710.1111/jth.14491Open DOISearch in Google Scholar
Kizilocak H, Yukhtman CL, Marquez-Casas E, et al Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol 2019; 10: 2040620719860025. doi: 10.1177/2040620719860025.KizilocakHYukhtmanCLMarquez-CasasEet alManagement of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assaysTher Adv Hematol201910204062071986002510.1177/2040620719860025Open DOISearch in Google Scholar
Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv 2019; 3: 1722–4. doi: 10.1182/ bloodadvances.2019000228.SeamanCDRagniMVEmicizumab use in major orthopedic surgeryBlood Adv201931722410.1182/bloodadvances.2019000228Open DOISearch in Google Scholar
